Last reviewed 2026-05-27 · How we verify

Azo Gantrisin (sulfafurazole)

Alra · FDA-approved active Under review Quality 10/100

Azo Gantrisin (generic name: sulfafurazole) is a Sulfonamide Antimicrobial drug developed by Alra. It is currently FDA-approved (first approved 1971) for Acute otitis media, Chancroid, Chlamydia Cervicitis.

Azo Gantrisin is a small molecule inhibitor of bacterial dihydropteroate synthase, classified as a sulfonamide antibacterial. It is used to treat a wide range of bacterial infections, including both Gram-negative and Gram-positive organisms.

At a glance

Generic name	sulfafurazole
Sponsor	Alra
Drug class	Sulfonamide Antimicrobial
Target	Endothelin-1 receptor
Therapeutic area	Immunology
Phase	FDA-approved
First approval	1971

Approved indications

Acute otitis media
Chancroid
Chlamydia Cervicitis
Chlamydial conjunctivitis
Falciparum malaria
Haemophilus Influenzae Acute Otitis Media
Infective otitis media
Meningococcal meningitis
Nocardiosis
Pneumococcal Acute Otitis Media
Trachoma
Urethritis due to Chlamydia trachomatis
Urinary tract infectious disease

Common side effects

No common side effects on file.

Drug interactions

methotrexate
pralatrexate
warfarin

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Azo Gantrisin CI brief — competitive landscape report
Azo Gantrisin updates RSS · CI watch RSS
Alra portfolio CI

Frequently asked questions about Azo Gantrisin

What is Azo Gantrisin?

Azo Gantrisin (sulfafurazole) is a Sulfonamide Antimicrobial drug developed by Alra, indicated for Acute otitis media, Chancroid, Chlamydia Cervicitis.

What is Azo Gantrisin used for?

Azo Gantrisin is indicated for Acute otitis media, Chancroid, Chlamydia Cervicitis, Chlamydial conjunctivitis, Falciparum malaria.

Who makes Azo Gantrisin?

Azo Gantrisin is developed and marketed by Alra (see full Alra pipeline at /company/alra).

What is the generic name of Azo Gantrisin?

sulfafurazole is the generic (nonproprietary) name of Azo Gantrisin.

What drug class is Azo Gantrisin in?

Azo Gantrisin belongs to the Sulfonamide Antimicrobial class. See all Sulfonamide Antimicrobial drugs at /class/sulfonamide-antimicrobial.

When was Azo Gantrisin approved?

Azo Gantrisin was first approved on 1971.

What development phase is Azo Gantrisin in?

Azo Gantrisin is FDA-approved (marketed).

What does Azo Gantrisin target?

Azo Gantrisin targets Endothelin-1 receptor and is a Sulfonamide Antimicrobial.

Drug class: All Sulfonamide Antimicrobial drugs
Target: All drugs targeting Endothelin-1 receptor
Manufacturer: Alra — full pipeline
Therapeutic area: All drugs in Immunology
Indication: Drugs for Acute otitis media
Indication: Drugs for Chancroid
Indication: Drugs for Chlamydia Cervicitis

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing